immatics biotechnologies GmbH (4A3) — Strategic Asset Allocation Index
immatics biotechnologies GmbH (4A3) has a Strategic Asset Allocation Index of 19.2% as of June 2023. Strategic assets (PP&E of €41.94 Million plus long-term investments of €-) total €41.94 Million, measured against net assets of €218.21 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See debt-free asset ratio of immatics biotechnologies GmbH to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
immatics biotechnologies GmbH Strategic Asset Allocation Index (2020–2022)
This chart shows how immatics biotechnologies GmbH's Strategic Asset Allocation Index has evolved across 3 annual periods from 2020 to 2022. As of June 2023, the index stands at 19.2%, representing strategic assets of €41.94 Million against net assets of €218.21 Million EUR. For live market cap and overall valuation, see immatics biotechnologies GmbH market cap and net worth.
Annual Strategic Asset Allocation Index for immatics biotechnologies GmbH (2020–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for immatics biotechnologies GmbH from 2020 to 2022, covering 3 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See 4A3 book value for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (EUR) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 12.4% | €26.49 Million | €26.49 Million | €- | €213.16 Million | ▼ -72.7 pp |
| 2021 | 85.1% | €20.49 Million | €20.49 Million | €- | €24.06 Million | ▲ +71.7 pp |
| 2020 | 13.4% | €14.02 Million | €14.02 Million | €- | €104.26 Million | — |